跳至主要内容
临床试验/NCT05506254
NCT05506254进行中(未招募)不适用

A Long-term Follow-up Study of Patients in LogicBio Clinical Trials for Methylmalonic Acidemia Characterized by MMUT Mutations Who Received hLB-001

Alexion Pharmaceuticals, Inc.4 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2022年7月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
4
试验地点
4
主要终点
Incidence of treatment emergent adverse events

研究概览

简要总结

This is a non-interventional long-term follow-up study of patients who have participated in LogicBio studies for the treatment of MMA and received hLB-001

详细描述

Patients will be followed for a period of 15 years which includes the duration of time that the patient was in the treatment study.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participant has previously participated in a LogicBio clinical trial and received hLB-001.

排除标准

  • 未提供

研究组 & 干预措施

Patients who have previously received hLB-001

干预措施: hLB-001 (Drug)

结局指标

主要结局

Incidence of treatment emergent adverse events

时间窗: 15 years

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验